NeurAxis, Inc.

Equities

NRXS

US64134X2018

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 01:40:00 15/06/2024 am IST			5-day change	1st Jan Change
2.97 ^USD	-1.00%		-0.67%	+11.24%

07/06	NeurAxis Submits Application to FDA to Expand IB-Stim Label	MT
22/05	Earnings Flash (NRXS) NEURAXIS Posts Q1 Revenue $646,635	MT

NeurAxis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

April 10, 2024 at 01:58 am IST

NeurAxis, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 2.46 million compared to USD 2.68 million a year ago. Net loss was USD 14.63 million compared to USD 4.78 million a year ago.

Latest news about NeurAxis, Inc.

NeurAxis Submits Application to FDA to Expand IB-Stim Label	07/06	MT
Earnings Flash (NRXS) NEURAXIS Posts Q1 Revenue $646,635	22/05	MT
Neuraxis, Inc. Provides Earnings Guidance for Late 2024 and 2025	22/05	CI
NeurAxis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	21/05	CI
NeurAxis, Inc. Terminates Dan Clarence as Chief Operating Officer	17/04	CI
NeurAxis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	10/04	CI
NeurAxis, Inc. Provides Revenue Guidance in Late 2024 and into 2025	10/04	CI
NeurAxis, Inc. Announces IB-Stim Results from A Large, Pediatric, Multi-Center Registry	27/03	CI
Neuraxis, Inc. Appoints Kristin Ferge to the Board	11/03	CI
Top Premarket Decliners	12/02	MT
Certain Common Stock of NeurAxis, Inc. are subject to a Lock-Up Agreement Ending on 5-FEB-2024.	05/02	CI
Certain Preferred Stock of NeurAxis, Inc. are subject to a Lock-Up Agreement Ending on 5-FEB-2024.	05/02	CI
Certain Options of NeurAxis, Inc. are subject to a Lock-Up Agreement Ending on 5-FEB-2024.	05/02	CI
Certain Warrants of NeurAxis, Inc. are subject to a Lock-Up Agreement Ending on 5-FEB-2024.	05/02	CI
NeurAxis Names Timothy Henrichs Finance Chief	31/01	MT
NeurAxis, Inc. Announces Resignation of Timothy Henrichs as Independent Director	31/01	CI
NeurAxis, Inc. Appoints Timothy Henrichs as Chief Financial Officer, Effective February 5, 2024	31/01	CI
NeurAxis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	21/11	CI
NeurAxis, Inc. announced that it expects to receive $3 million in funding from Flagstaff International, Inc	09/11	CI
NeurAxis Signs Option Deal for University of Michigan's Rectal Expulsion Device	08/11	MT
NeurAxis, Inc. Signs Exclusive Option Agreement with University of Michigan for Innovative Gastrointestinal Device	08/11	CI
NeurAxis, Inc. Announces Results of Comparative Study of IB-Stim and Standard Medical Therapy in Adolescents with Functional Abdominal Pain Disorders	26/23/26	CI
Earnings Flash (NRXS) NEURAXIS Posts Q2 Revenue $646,000	21/23/21	MT
NeurAxis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21/23/21	CI
NeurAxis, Inc.(NYSEAM:NRXS) added to S&P TMI Index	18/23/18	CI

Chart NeurAxis, Inc.

Duration

Period

More charts

Company Profile

Neuraxis, Inc. is a medical technology company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It is engaged in advancing science with its IB-Stim therapy, based on its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, which was developed internally by the Company. The Company's first product, IB-Stim, is a PENFS system intended to be used in patients 11-18 years of age with functional abdominal pain associated with IBS. The IB-Stim is intended to be used for 120 hours per week for three consecutive weeks, and not to exceed four weeks, through application to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination, as an aid in the reduction of pain when combined with other therapies for IBS. Other indications in its pipeline are comprised of functional nausea in children, post-concussion syndrome in children, and cyclic vomiting syndrome in children.

Sector

Medical Equipment, Supplies & Distribution

Calendar

19/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.97 USD

Average target price

7.5 USD

Spread / Average Target

+152.53%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Medical Equipment

	1st Jan change	Capi.
NEURAXIS, INC.	+11.24%	19.74M
SHOCKWAVE MEDICAL	+75.69%	12.57B
PENUMBRA, INC.	-25.35%	7.28B
MASIMO CORPORATION	+15.77%	7.2B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+14.52%	5.47B
GETINGE AB	-18.50%	4.73B
APT MEDICAL INC.	+14.91%	4.09B
ASAHI INTECC CO., LTD.	-23.67%	3.78B
INARI MEDICAL, INC.	-30.22%	2.63B
NOVOCURE LIMITED	+42.93%	2.3B

Medical Equipment